Briefing
Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy in HER2-positive metastatic breast cancer: initial results from HER2-CR study
Initial results from the prospective HER2-CR registry (NCT06663787) in 37 evaluable patients with long-term CR/PR on anti-HER2 therapy for HER2-positive metastatic breast cancer found that 129 of 142 plasma samples (91%) were negative on Signatera Genome and 30 of 37 patients (81%) were negative at every assessment; all 23 patients without radiographic residual disease remained ctDNA-negative, while persistent positivity was more often accompanied by progression.